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Abstract The aim of this study was to evaluate the
adequacy of family history taking in epithelial ovarian
cancer (EOC) patients and to identify factors that deter-
mine adequacy. Furthermore, the validity of family history
taking was assessed by comparison with self-administered
questionnaires. Medical records of all 1,112 EOC patients
registered by the nation-wide cancer registry and diagnosed
in eleven Dutch hospitals between 1996 and 2006 were
reviewed. Adequate family history taking was defined as a
written notification of the presence or absence of relatives
with breast or ovarian cancer. Factors that were correlated
with family history taking were identified using univariable
and multivariable logistic regression. 147 patients filled in
a postal questionnaire. An adequate family history was
taken in 41% of all cases. Younger age, an academic
hospital and having undergone surgery and/or chemother-
apy were associated with adequate family history taking.
The comparison with self-administered questionnaires
showed a disagreement in 64% mainly due to missing data
in medical records. Documentation on family history is
either absent or inadequate in the medical records in the
majority of EOC patients. These data urge for better uptake
of hereditary cancer risk assessment. Different strategies
for this assessment like improved family history taking and
genetic testing in EOC patients should be explored.
Keywords Family history taking  Ovarian neoplasms 
Hereditary neoplastic syndromes
Introduction
Although many theories have been proposed, the mecha-
nism of ovarian carcinogenesis is still unclarified. Several
risk factors for epithelial ovarian cancer (EOC) are identi-
fied. However, by far the most significant risk factor for
EOC is a family history of this disease; a woman with one
first-degree relative with ovarian cancer has a three-fold
increased risk of developing EOC herself [1]. It is estimated
that approximately 10–15% of ovarian cancer is hereditary
[2–5]. At least two hereditary syndromes predispose to
familial ovarian cancer: the hereditary breast-ovarian can-
cer (HBOC) syndrome and the Lynch syndrome. Mutations
in the BRCA1 and BRCA2 tumor suppressor genes account
for 65–85% of all hereditary ovarian cancers. A recent
population-based study showed a combined BRCA1 and
BRCA2 mutation frequency of 13.3% among 1,342 women
with ovarian cancer [6]. The lifetime risk of ovarian cancer
in BRCA1 and BRCA2 mutation carriers is approximately
40–60 and 10–25%, respectively [7, 8]. Mutations in
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mismatch repair genes MLH1, MSH2, MSH6, PMS1, and
PMS2 in the Lynch syndrome account for 10–15% of
hereditary ovarian cancers, with a lifetime risk of 8–10% of
developing ovarian cancer [2, 8, 9].
To date, reliable screening methods for ovarian cancer are
not available and screening for ovarian cancer in the general
population does not reduce mortality [10]. Even in high risk
populations screening has a poor ability to detect early stage
disease [11]. The only proven method to dramatically reduce
the incidence of ovarian cancer in high-risk patients is a
prophylactic bilateral salpingo-oophorectomy (BSO) [12,
13]. BSO is indicated in BRCA-carriers around the age of 40.
It not only reduces the risk of ovarian cancer by up to 96%
but also halves the risk of breast cancer (BC) in pre-meno-
pausal women [12–15].
The primary tool to trace hereditary cancer is family
history taking. It has several advantages over genetic tests
including lower costs, greater acceptability and a reflection
of shared genetic and environmental factors [16]. More-
over, criteria for genetic testing rely almost exclusively on
family history information [17]. In various studies how-
ever, the question is raised how accurate family history is
to predict mutation status [3, 4, 6]. Several reasons are
given for a low validity of family history taking as diag-
nostic test for hereditary cancer, i.e. small families or
families with few women, changeable penetrance, sporadic
cancers, new mutations or inadequate family history tak-
ing. There is no literature available on the adequacy of
family history taking in EOC patients. Studies addressing
this issue have mainly focused on colorectal and BC.
The purpose of this population-based study was to
describe adequacy of family history taking in EOC patients
and to identify factors that determine this adequacy. Sec-
ondly, we aimed to acquire insight in the reliability of
presence or absence of written notifications of family his-
tory in medical records by comparing data in medical
records with data collected thru self-administered
questionnaires.
Patients and methods
To evaluate adequacy of family history taking in EOC
patients and factors that determine this adequacy, we used
population-based data from a retrospective study in 11
hospitals in the eastern part of the Netherlands: one uni-
versity clinic and ten community hospitals. The population-
based Netherlands Cancer Registry (NCR) registered 1,178
patients with primary EOC in these hospitals between 1996
and 2006. Hospital records of the patients were studied by
trained registrars using a standard case record form. Data
on patient characteristics, tumor characteristics, therapy
and recurrence were collected. After excluding 66 patients
without histological confirmed EOC, data of a total number
of 1,112 patients were available. Data on family history
taking included degree and age at diagnosis of all relatives
diagnosed with EOC, BC, or colorectal cancer (CRC). For
this study adequate family history taking was defined as a
written notification of the presence or absence of relatives
with breast or ovarian cancer. Factors that may be corre-
lated with family history taking were tested using uni-
variable logistic regression analysis. Factors tested were;
age of the patient at diagnosis (\40, 40–60, [60 year),
hospital type (general, teaching, university hospital), year
of diagnosis (1996–1999, 2000–2003, 2004–2006), men-
strual state (pre- or postmenopausal), cancer in patient’s
history (yes or no), BC in patient’s history (yes or no),
cervical cancer in patient’s history (yes or no), endometrial
cancer in patient’s history (yes or no), colon cancer in
patient’s history (yes or no), CA125 at diagnosis (B35 or
[35), Risk of Malignancy Index (B200 or [200), Kar-
nofsky score (B70 or [70), stage of disease (early =
FIGO \ IIb or advanced = FIGO C IIb), surgery (yes or
no), chemotherapy (yes or no), histology (serous, endome-
trioid, mucinous, adenocarcinoma not otherwise specified
or other), grade of differentiation (grade I or II or III),
number of recurrences (0, 1, 2, 3 or C4) and inclusion
in a trial (yes or no). All P values presented are two-sided,
and associations were considered significant if the P value
\0.05. Since correlation between certain factors was
expected all significant indicators (P \ 0.05) were entered
in a multivariable model using a stepwise forward
approach. Statistical analyses were performed using Sta-
tistical Package for Social Sciences 16.0 for Microsoft
Windows (SPSS Inc.).
To measure the reliability of presence or absence of
written notifications on family history in medical records,
we compared data in the medical files with data collected
by self-administered questionnaires. In 2008, these ques-
tionnaires were sent to all living patients diagnosed with
ovarian cancer between 1989 and 2008 in seven of the 11
hospitals. The questionnaire database included 308 patients
of whom 150 were also included in the above described
EOC database. The other 158 cases were diagnosed before
1996 or after 2006, or were non-EOC cases (Fig. 1).
Another three cases were excluded since data on family
history were missing in both the EOC database and the
questionnaires. Data on family history taking included type
of malignancy and age at diagnosis of first-degree relatives.
A comparison was made based on the number of relatives
with a malignancy, the type of malignancy (being BC,
EOC or CRC), and age at diagnosis. Cancer cases among
family members mentioned in the self-questionnaire but
diagnosed after the last follow-up date of the patient were
excluded. Agreement between the databases on number of
relatives with a malignancy, type of malignancy, and age at
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diagnosis with an acceptable margin of error of 5 years,
was defined as total agreement. Partial agreement was
defined as agreement on number of relatives with a
malignancy and type of malignancy.
Results
In total 1,112 medical records were studied. Figure 1
shows an overview of this database and the other databases
used in this study. For 41% (456/1,112) of the cases,
documentation on family history of breast and ovarian
cancer was found in the medical records. Table 1 shows
characteristics of patients with or without an adequate
documentation on family history. Univariable logistic
regression analysis showed age, hospital type, year of
diagnosis, menstrual state, BC in the past, Karnofsky score,
histology, having surgery or chemotherapy, recurrence, and
inclusion in a trial, to be significantly correlated with
adequacy of family history taking. Multivariable logistic
regression analysis identified age, hospital type, and having
surgery or chemotherapy, as significant independent prog-
nostic factors (Table 2). Patients who were younger,
diagnosed in a university hospital, or who underwent
chemotherapy and/or surgery, were more likely to have an
adequate documentation on family history.
147 cases in the EOC database also completed a ques-
tionnaire. In 36% (53/147) of the cases, full agreement was
found regarding the number and types of malignancy, as
well as ages at diagnoses within 5 years. Another five per
cent (8/147) agreement was found for the number and type
of malignancy in relatives. In 59% (86/147) of the cases, the
information on family cancer history was discordant. In
those 86 cases, medical records reported more malignancies
than self-administered questionnaires in 11% (9/86), self-
administered questionnaires reported more malignancies in
Figure 1. Overview of databases used in this study
EOC cases (N=1112)
diagnosed 1996-2006
medical records
OC cases (N=308)
diagnosed 1989-2008
self-administered 
questionnaires
150 EOC cases
Included EOC cases (N=147)
Cases excluded (N=158): 
- diagnosed before 1996 or            
after 2006 (N=116)
- not histologically confirmed 
EOC (N=42)
Cases excluded (N=962):
patients who died before 2008
Cases excluded (N=3): 
family history data missing in 
both databases
BC/OC cases (N=5200)
diagnosed 2005-2008
registered by cancer
registry
OC cases 
(N=342)
BC cases 
(N=4858)
Fig. 1 Overview of databases used in this study. EOC epithelial ovarian cancer, OC ovarian cancer, BC breast cancer
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23% (20/86), and data were missing in the medical records
where the self-administered questionnaires reported a neg-
ative family history in 66% (57/86).
Discussion
Our population-based study shows that, adequate docu-
mentation on family history was present in only 41% of all
medical records of EOC patients. This percentage is in
agreement with ranges found in literature regarding
patients with CRC and data required in primary care set-
tings [17–20]. In univariable analysis a slight improvement
over time was seen which is encouraging however family
history is still poorly recorded. This is especially true when
taking into account our limited definition of an adequate
history covering the majority of hereditary ovarian cancers,
namely the BRCA mutation carriers, but leaving others
unattended. Previous studies on CRC defined adequate
family history taking by presence of a notification of
Table 1 Associations between patient, tumor and treatment charac-
teristics and adequacy of family history taking in univariable logistic
regression analysis (n = 1,112)
Characteristics Adequate
N(%)
Inadequate
N(%)
P value
Age (years) \0.01
[60 200 (32%) 429 (68%)
40–60 216 (52%) 202 (48%)
\40 39 (66%) 20 (34%)
Hospital type \0.01
General hospital 182 (33%) 371 (67%)
Teaching hospital 188 (42%) 264 (58%)
University hospital 86 (81%) 20 (19%)
Year of diagnosis 0.019
1996–1999 166 (38%) 274 (62%)
2000–2003 181 (41%) 265 (59%)
2004–2006 109 (49%) 113 (51%)
Menstrual state \0.01
Premenopausal 113 (57%) 86 (43%)
Postmenopausal 311 (37%) 527 (63%)
Cancer in patients history 0.230
No 372 (41%) 536 (59%)
Yes 82 (46%) 97 (54%)
Breast cancer in patients history \0.01
No 410 (41%) 599 (59%)
Yes 44 (56%) 34 (44%)
Colon cancer in patients history 0.464
No 448 (42%) 621 (58%)
Yes 6 (33%) 12 (67%)
Endometrial cancer in history 0.131
No 443 (42%) 607 (58%)
Yes 11 (30%) 26 (70%)
Cervical cancer in patients
history
0.593
No 448 (42%) 628 (58%)
Yes 5 (50%) 5 (50%)
CA-125 at diagnosis 0.174
B35 60 (49%) 63 (51%)
[35 360 (42%) 491 (58%)
Risk of malignancy index (RMI) 0.984
B200 56 (44%) 71 (56%)
[200 286 (44%) 364 (56%)
Karnofsky score \0.01
\70 51 (24%) 159 (76%)
C70 395 (46%) 459 (54%)
Stage 0.602
Early (\IIb) 113 (43%) 152 (57%)
Advanced (CIIb) 316 (44%) 394 (56%)
Chemotherapy \0.01
No 98 (25%) 297 (75%)
Yes 357 (50%) 359 (50%)
Table 1 continued
Characteristics Adequate
N(%)
Inadequate
N(%)
P value
Surgery \0.01
No 40 (19%) 166 (81%)
Yes 416 (46%) 488 (54%)
Histology \0.01
Serous 205 (48%) 221 (52%)
Mucinous 37 (42%) 52 (58%)
Endometrioid 78 (47%) 89 (53%)
Adenocarcinoma NOSa 84 (33%) 169 (67%)
Otherb 45 (40%) 67 (60%)
Grade of differentiation 0.297
1 56 (41%) 81 (59%)
2 100 (42%) 140 (58%)
3 225 (47%) 257 (53%)
Number of recurrence \0.01
0 229 (35%) 426 (65%)
1 145 (47%) 163 (53%)
2 58 (53%) 51 (47%)
3 14 (61%) 9 (39%)
C4 10 (59%) 7 (41%)
Inclusion in trial 0.034
No 421 (40%) 623 (60%)
Yes 33 (54%) 28 (46%)
Adequate family history taking was defined as a written notification
of the presence or absence of relatives with breast or ovarian cancer
a Adenocarcinoma not otherwise specified
b Clear cell, Brenner, mixed, undifferentiated and other rare epithelial
types
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relatives with CRC only [18, 20]. Therefore, we feel that
we used an appropriate definition for adequate family
history taking in this study, but encourage clinicians to
apply a much broader definition.
We believe a comprehensive adequate family history
should include information on first and second degree
relatives, the type of tumor they developed (especially
colorectal or endometrial carcinoma) and the age at onset.
Since families are getting smaller one should also note the
total number of first and second-degree relatives to put it in
perspective. An additional problem is that with the
decreasing number of relatives family history taking is
expected to be less accurate in the future. It is important to
ask about second degree relatives since 50% of the muta-
tions are paternally derived and the fathers are likely to be
unaffected. Though it is known that information on second
degree relatives is less reliable than information on first
degree relatives [21]. Also the absence of malignancies
should be noted. In case of suspicion of hereditary cancer
one should refer the patient to a specialist in the field of
clinical genetics.
We defined four factors to be independently correlated
with adequacy of family history taking. Having chemo-
therapy or surgery often requires involvement of more
specialists, longer therapeutic relationships and hospital-
ization, leading to more opportunities to ask about family
history. Regarding age, in younger patients family history
taking is probably more accurate because physicians are
aware of an earlier age at onset in the majority of mutation
carriers. We urge specialists to keep in mind the possibility
of a hereditary malignancy, even in the elderly patients.
With respect to hospital type, specialized gynecologists in
academic hospitals more often recorded family history.
Since it is shown that treatment by a gynecologic
oncologist improves outcome, more and more EOC
patients will be treated by specialized gynecologists and
discussed in multidisciplinary tumor boards, which even-
tually may improve adequacy of history taking.
With the result of the multivariable analysis the question
raised if gynecologists perform worse in family history
taking compared to other physicians. To answer this
question we again used the database of the NCR. Family
history data of all 4,858 BC and all 342 EOC patients
diagnosed between 2005 and 2008 were compared. Data,
extracted from medical records, included number of first-
degree relatives with the same malignancy (being BC or
EOC), age of the youngest relative with the same malig-
nancy and number of first-degree relatives with another
malignancy. In 30% (104/342) of all EOC patients, com-
pared with 64% (3,103/4,858) of all BC patients, docu-
mentation on presence or absence of first-degree relatives
with the same malignancy was found. 24% (81/342) of
EOC patients and 20% (989/4,858) of BC patients had any
documentation in their medical record about first-degree
relatives with other malignancies. So family history
regarding first-degree relatives with the same malignancy
was taken twice more frequently in BC patients. Breast
cancer is much more common compared to ovarian cancer.
As a result, patients can be more aware of BC in their
family and both patient and physician can be more forth-
coming towards this subject. The clinician and patient can
also be more aware of BC as a hereditary cancer, since
there has been a lot of attention for this subject. Family
history taking on first-degree relatives with another
malignancy is as likely to be forgotten by surgeons in BC
patients as by gynecologists in EOC patients.
Although the large sample size is an apparent strength of
this study, we are aware of some limitations. It is possible
Table 2 Associations between
patient, tumor and treatment
characteristics and adequacy of
family history taking in
multivariable logistic regression
analysis (n = 1,112)
Adequate family history taking
was defined as a written
notification of the presence or
absence of relatives with breast
or ovarian cancer
Characteristics Adequate Inadequate Odds ratio 95% CI
Lower Upper
Age
[60 200 (32%) 429 (68%) 1.00
40–60 216 (52%) 202 (48%) 1.65 1.23 2.22
\40 39 (66%) 20 (34%) 3.27 1.70 6.26
Hospital type
General hospital 182 (33%) 371 (67%) 1.00
Teaching hospital 188 (42%) 264 (58%) 1.63 1.22 2.19
University hospital 86 (81%) 20 (19%) 8.74 4.84 15.79
Surgery
No 40 (19%) 166 (81%) 1.00
Yes 416 (46%) 488 (54%) 1.68 1.02 2.76
Chemotherapy
No 98 (25%) 297 (75%) 1.00
Yes 357 (50%) 359 (50%) 2.25 1.63 3.12
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that specialists did not register anything in the absence of
relatives with a malignancy. In that case the family history
was considered to be absent although it in fact was
examined correctly. In order to determine this possible
bias, we compared the data with self-administered ques-
tionnaires. Ziogas et al. [21] showed that reliability of self-
reported family history taking varies by cancer site and by
degree of relative. For first-degree relatives, family history
provided by patients was accurate in 83.3% for ovarian
cancer. Murff et al. [22] supported the first statement but
also states that negative family history reports for ovarian
cancer are less useful. Especially abdominal malignancies
are reported inaccurately probably because many organs
are within the abdominal cavity and it is often referred to as
‘‘abdominal cancer’’ [23]. In the current study, we were
unable to assess the reliability of family history taking by
verifying it with a population-based registration and
therefore chose a comparison with self-administered
questionnaires.
Data of 147 EOC cases of mainly long-term ovarian
cancer survivors were studied. In nearly 60% of the cases
no agreement was found which was largely due to missing
data in the EOC database in absence of any relatives with a
malignancy in the questionnaires. Data from medical
records were gathered in 2007 and the questionnaires were
filled out by patients in 2008. It is likely that if gynecol-
ogists asked about family history, they did so in the early
stages of treatment and never pursued it over time. Patients
may also have developed more awareness on cancer in
their family during the years since their diagnoses. As
mentioned previously, these 147 cases were mainly long-
term survivors. While analyzing data of these cases, 58%
of these patients showed an adequate documentation in
their medical records, compared to 41% in the whole EOC
group. An unselected patient group with respect to survival
may worsen the results in our study even more.
It is of upmost importance to have an accurate tool for
the identification of hereditary cancer. The risk of EOC can
currently not be reduced by screening but a prophylactic
BSO offered to high-risk patients can reduce the risk sig-
nificantly. BRCA mutation carriers also have an improved
sensitivity to platinum chemotherapy and novel therapeutic
agents such as poly (ADP-ribose) polymerase inhibitors
have increased activity in these patients [24]. High risk
patients however, need to be identified firstly. Our study
shows that family history taking over the last 10 years was
inadequate in the majority of EOC patients. Moreover, a
recent study shows that family histories change signifi-
cantly over time and updates on family history every
5–10 years are recommended [25]. Data on sensitivity of
family history as a predictor of mutation carrier status are
conflicting. In various studies all EOC patients both
underwent family history taking and genetic testing. The
proportion of BRCA gene mutation carriers having a first
or second degree relative with ovarian or BC varied from
92% [26] to 62–69% [4, 5]. It appears reasonable to offer
genetic testing to all non-mucinous EOC patients in order
to fully benefit from preventive measures like a BSO. But
since genetic testing is not routinely offered in many
countries and even when it is offered it is not performed in
all cases, there is still a place for family history taking.
Family history taking also plays an important role in the
counseling of patients with a possible hereditary tumor.
Moreover, patients with familial ovarian cancer but without
mutation can be offered a BSO. The upcoming of elec-
tronic health record systems can be helpful by turning
family history taking into a fixed item in consultations with
cancer patients. Further education is needed for the phy-
sician to increase awareness of hereditary cancer since
taking an adequate family history is still essential to pro-
vide high-standard care to patients with cancer and their
families even in the era of genetic testing.
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